New Discovery to Pave Way for New Class of AIDS Drug
A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. According to the World Health Organization, about 33 million people currently live with HIV infections.
Several drugs used to treat AIDS inhibit this HIV protease target, but drug-resistant mutants that impede the effectiveness of these drugs keep appearing and getting worse.
Utilizing computing power from 1.5 million devices networked through IBM’s World Community Grid, the new sites on the HIV protease are being used as docking targets for virtual screening experiments, in order to guide the development of these chemical compounds into a new class of potent HIV inhibitors.
There are no responses so far.
Leave your response